Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.

Robert W. Mays, M.D., Ph.D., Executive Vice President and Head of Regenerative Medicine & Neuroscience, will speak in a keynote panel at the Challenges and Opportunities for Mesenchymal Stem Cells digital conference on November 17. Dr. Mays will be speaking in his area of expertise, joining other industry experts to discuss clinical trial design, overcoming challenges in the clinical setting, and more.

The following are specific details regarding Athersys’ participation at the Challenges and Opportunities for Mesenchymal Stem Cells conference:

Event:	Challenges and Opportunities for Mesenchymal Stem Cells
Panel:	What are the Current Barriers for Success?
	Nitsan Halevy, CMO, Pluristem
Participants:	Robert Mays, Executive VP, Athersys
	Pawan Gupta, VP, Medical Affairs, Stempeutics
Date:	Thursday, November 17, 2022
Time:	8:05 AM Eastern Time
Location:	Virtual

A live video webcast of all content from the digital conference will be available for registered participants during the conference and for 10 business days post-event. Please visit https://informaconnect.com/challenges-and-opportunities-for-mscs/ for detailed conference information and registration.

Additionally, members of Athersys management will be attending A.G.P.’s Biotech Conference on November 30 and will be participating in one-on-one meetings with institutional investors registered with the conference. Investors interested in arranging a meeting with members of the Company’s management during the conference should contact [e-mail].